1. MicroRNA-1202 Is a Candidate Biomarker To Assist Selection of Patients for Therapy With a Left Ventricular Assist Device
- Author
-
A Mills, Andrew Morley-Smith, A. Simon, Steven Jacobs, John Pepper, Filip Rega, Thomas Thum, Bart Meyns, and Alexander R. Lyon
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,Transplantation ,medicine.medical_specialty ,Mobilization ,business.industry ,medicine.medical_treatment ,Endogeny ,CXCR4 ,Ventricular assist device ,Internal medicine ,microRNA ,Cardiology ,Medicine ,Biomarker (medicine) ,Surgery ,Stem cell ,Cardiology and Cardiovascular Medicine ,business - Abstract
s S235 level of SDF-1a at explant. CXCR4 expression remained unchanged following CF-LVAD support, however it tended to be lower in DM pts suggesting an impaired ability in endogenous stem cell mobilization. Conclusion: Chronic LVAD therapy down regulates SDF-1a expression likely as a consequence of effective unloading. DM pts exhibit the lowest levels of SDF-1a. Low SDF-1a expression may lead to impaired mobilization of endogenous stem cells and negatively affect myocardial recovery. Whether therapeutic SDF-1 administration in this setting could promote recovery should be further investigated.
- Published
- 2014
- Full Text
- View/download PDF